Target mutations and vaccines
By focusing on the most common and shared frameshift mutations across hereditary and sporadic MSI cancers Hubro Bioscience has established a proprietary neo-peptide technology platform. The core neoantigens of the proprietary technology platform cover frameshift mutation in TGFβR2, , ASTE1 and TAF1B. Additional targets are being explored.
The frameshift targeted technology platforms provides a solid basis for development of vaccines and diagnostic tests useful for cancer prevention.
Targeting shared neo-antigens in MSI-cancer
Click the image to zoom
Lead candidate vaccine FMPV3 is ready for phase 1 clinical develeopment
- Has a potential as a vaccine for prevention of herditary MSI cancers
- Lynch Syndrome – 55-80% risk of early onset of colon cancer with mean age of onset 44-61 years
fsp2: 24 amino acid designed neo-peptide
Fsp5: 33 amino acid target neo-antigen (TGFβR2) peptide
Tc: T cells,
APC: antigen presenting cell
PBMC: Peripheral blood mononuclear cell
SI: Stimulation index